Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| BIOMARIN PHARMACEUTICAL INCBMRN · Entity 2404 | Director · Chief Executive Officer | March 17, 2026 | March 19, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
BIOMARIN PHARMACEUTICAL INC
Report date March 17, 2026 · Filed March 19, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 214,635 |
Reported balance
After 2026-03-17 transaction · row 1
1 source rowRow 1 · 2026-03-17 · Tax withholding · Disposed 4,252 · Balance 214,635 |
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| March 17, 2026 Filed Mar 19, 2026 20:34 UTC | BIOMARIN PHARMACEUTICAL INC BMRN · Entity 2404 | Tax withholdingCommon Stock | 4,252 | $56.05 | $238,324.60 |
DisclosureSEC source: 0001628280-26-019847 · wk-form4_1773952468.xml · nonDerivative · entry 1 Hardy Alexander · CIK 0002001910 · Director · Chief Executive Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 214,635 Read SEC document |
| March 16, 2026 Filed Mar 18, 2026 00:43 UTC | BIOMARIN PHARMACEUTICAL INC BMRN · Entity 2404 | GrantStock Option (Right to Buy Common Stock) · Derivative | 89,200 | $0.00 Strike: $57.43 | $0.00 |
DisclosureSEC source: 0001628280-26-019006 · wk-form4_1773794583.xml · derivative · entry 3 Hardy Alexander · CIK 0002001910 · Director · Chief Executive Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 89,200 Underlying: Common Stock · 89,200 shares Expires 2036-03-15 F2 · derivative.exercise_date: Option grant vests 12/48th on March 16, 2027 and 1/48th on the 16th day of each month thereafter. Read SEC document |
| March 16, 2026 Filed Mar 18, 2026 00:43 UTC | BIOMARIN PHARMACEUTICAL INC BMRN · Entity 2404 | GrantCommon Stock | 62,440 | $0.00 | $0.00 |
DisclosureSEC source: 0001628280-26-019006 · wk-form4_1773794583.xml · nonDerivative · entry 2 Hardy Alexander · CIK 0002001910 · Director · Chief Executive Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 218,887 F1 · price: Restricted stock units granted March 16, 2026. Price not applicable. Read SEC document |
| March 13, 2026 Filed Mar 18, 2026 00:43 UTC | BIOMARIN PHARMACEUTICAL INC BMRN · Entity 2404 | Tax withholdingCommon Stock | 2,941 | $58.51 | $172,077.91 |
DisclosureSEC source: 0001628280-26-019006 · wk-form4_1773794583.xml · nonDerivative · entry 1 Hardy Alexander · CIK 0002001910 · Director · Chief Executive Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 156,447 Read SEC document |
| December 01, 2025 Filed Dec 2, 2025 23:29 UTC | BIOMARIN PHARMACEUTICAL INC BMRN · Entity 2404 | Tax withholdingCommon Stock | 16,570 | $55.03 | $911,847.10 |
DisclosureSEC source: 0001628280-25-054856 · wk-form4_1764718145.xml · nonDerivative · entry 2 Hardy Alexander · CIK 0002001910 · Director · Chief Executive Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 159,388 Read SEC document |
| April 30, 2025 Filed Dec 2, 2025 23:29 UTC | BIOMARIN PHARMACEUTICAL INC BMRN · Entity 2404 | GrantCommon Stock | 375 | $54.14 | $20,301.38 |
DisclosureSEC source: 0001628280-25-054856 · wk-form4_1764718145.xml · nonDerivative · entry 1 Hardy Alexander · CIK 0002001910 · Director · Chief Executive Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 175,958 F1 · date: Represents the shares acquired by the reporting person on April 30, 2025, pursuant to the issuer's Employee Stock Purchase Plan. Read SEC document |
| March 17, 2025 Filed Mar 18, 2025 22:17 UTC | BIOMARIN PHARMACEUTICAL INC BMRN · Entity 2404 | GrantStock Option (Right to Buy Common Stock) · Derivative | 61,750 | $0.00 Strike: $71.55 | $0.00 |
DisclosureSEC source: 0001048477-25-000027 · wk-form4_1742336248.xml · derivative · entry 3 Hardy Alexander · CIK 0002001910 · Director · Chief Executive Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 61,750 Underlying: Common Stock · 61,750 shares Expires 2035-03-16 F2 · derivative.exercise_date: Option grant vests 12/48th on March 17, 2026 and 1/48th on the 17th day of each month thereafter. Read SEC document |
| March 17, 2025 Filed Mar 18, 2025 22:17 UTC | BIOMARIN PHARMACEUTICAL INC BMRN · Entity 2404 | GrantCommon Stock | 44,360 | $0.00 | $0.00 |
DisclosureSEC source: 0001048477-25-000027 · wk-form4_1742336248.xml · nonDerivative · entry 2 Hardy Alexander · CIK 0002001910 · Director · Chief Executive Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 175,583 F1 · price: Restricted stock units granted March 17, 2025. Price not applicable. Read SEC document |
| March 14, 2025 Filed Mar 18, 2025 22:17 UTC | BIOMARIN PHARMACEUTICAL INC BMRN · Entity 2404 | Tax withholdingCommon Stock | 2,933 | $69.44 | $203,667.52 |
DisclosureSEC source: 0001048477-25-000027 · wk-form4_1742336248.xml · nonDerivative · entry 1 Hardy Alexander · CIK 0002001910 · Director · Chief Executive Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 131,223 Read SEC document |
| November 29, 2024 Filed Dec 3, 2024 23:15 UTC | BIOMARIN PHARMACEUTICAL INC BMRN · Entity 2404 | Tax withholdingCommon Stock | 14,295 | $66.03 | $943,898.85 |
DisclosureSEC source: 0001048477-24-000156 · wk-form4_1733267696.xml · nonDerivative · entry 2 Hardy Alexander · CIK 0002001910 · Director · Chief Executive Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 134,156 Read SEC document |
| October 31, 2024 Filed Dec 3, 2024 23:15 UTC | BIOMARIN PHARMACEUTICAL INC BMRN · Entity 2404 | GrantCommon Stock | 300 | $56.01 | $16,802.10 |
DisclosureSEC source: 0001048477-24-000156 · wk-form4_1733267696.xml · nonDerivative · entry 1 Hardy Alexander · CIK 0002001910 · Director · Chief Executive Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 148,451 F1 · date: Represents the shares acquired by the reporting person on October 31, 2024, pursuant to the issuer's Employee Stock Purchase Plan. Read SEC document |
| March 15, 2024 Filed Mar 20, 2024 00:42 UTC | BIOMARIN PHARMACEUTICAL INC BMRN · Entity 2404 | GrantStock Option (Right to Buy Common Stock) · Derivative | 44,050 | $0.00 Strike: $83.87 | $0.00 |
DisclosureSEC source: 0001048477-24-000040 · wk-form4_1710895361.xml · derivative · entry 2 Hardy Alexander · CIK 0002001910 · Director · Chief Executive Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 44,050 Underlying: Common Stock · 44,050 shares Expires 2034-03-14 F2 · derivative.exercise_date: Option grant vests 12/48th on March 15, 2025 and 1/48th on the 15th day of each month thereafter. Read SEC document |
| March 15, 2024 Filed Mar 20, 2024 00:42 UTC | BIOMARIN PHARMACEUTICAL INC BMRN · Entity 2404 | GrantCommon Stock | 32,780 | $0.00 | $0.00 |
DisclosureSEC source: 0001048477-24-000040 · wk-form4_1710895361.xml · nonDerivative · entry 1 Hardy Alexander · CIK 0002001910 · Director · Chief Executive Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 148,151 F1 · price: Restricted stock units granted March 15, 2024. Price not applicable. Read SEC document |
| December 01, 2023 Filed Dec 5, 2023 22:13 UTC | BIOMARIN PHARMACEUTICAL INC BMRN · Entity 2404 | GrantStock Option (Right to Buy Common Stock) · Derivative | 150,529 | $0.00 Strike: $92.42 | $0.00 |
DisclosureSEC source: 0001048477-23-000055 · wk-form4_1701814423.xml · derivative · entry 3 Hardy Alexander · CIK 0002001910 · Director · Chief Executive Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 150,529 Underlying: Common Stock · 150,529 shares Expires 2033-11-30 F2 · derivative.exercise_date: Option grant vests 12/48th on December 1, 2024 and 1/48th on the 1st day of each month thereafter. Read SEC document |
| December 01, 2023 Filed Dec 5, 2023 22:13 UTC | BIOMARIN PHARMACEUTICAL INC BMRN · Entity 2404 | GrantCommon Stock | 47,332 | $0.00 | $0.00 |
DisclosureSEC source: 0001048477-23-000055 · wk-form4_1701814423.xml · nonDerivative · entry 2 Hardy Alexander · CIK 0002001910 · Director · Chief Executive Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 115,371 F1 · price: Restricted stock units granted on December 1, 2023. Price not applicable. Read SEC document |
| December 01, 2023 Filed Dec 5, 2023 22:13 UTC | BIOMARIN PHARMACEUTICAL INC BMRN · Entity 2404 | GrantCommon Stock | 68,039 | $0.00 | $0.00 |
DisclosureSEC source: 0001048477-23-000055 · wk-form4_1701814423.xml · nonDerivative · entry 1 Hardy Alexander · CIK 0002001910 · Director · Chief Executive Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 68,039 F1 · price: Restricted stock units granted on December 1, 2023. Price not applicable. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.